• 1
    Schiffer CA. Acute myeloid leukemia in adults: Where do we go from here? Cancer Chemother Pharmacol 2001; 48( suppl): S45S52.
  • 2
    Montgomery JA,Shortnacy-Fowler AT,Clayton SD,Riordan JM, et al. Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-β-D-arabinofuranosyladenine. J Med Chem 1992; 35: 397401.
  • 3
    Parker WB,Allan PW,Hassan AE,Secrist JAIII, et al. Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther 2003; 10: 2329.
  • 4
    Carson DA,Wasson DB,Esparza LM,Carrera CJ, et al. Oral antilymphocyte activity and induction of apoptosis bu 2-chloro-2′.arabino-fluoro-2′deoxyadenosine. Proc Natl Acad Sci USA 1992; 89: 29702974.
  • 5
    Kantarjian HM,Gandhi V,Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003; 21: 11671173.
  • 6
    Kantarjian HM,Gandhi V,Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003; 102: 23792386.
  • 7
    Jeha S,Gaynon P,Razzouk B, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006; 24: 19171923.
  • 8
    Cooper T,Ayres M,Nowak B, et al. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol 2005; 55: 361368.
  • 9
    Gandhi V,Kantarjan H,Faderl S, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res 2003; 9: 63356342.
  • 10
    Foran J,Faderl S,Wetzler M, et al. A phase II, open-label study of clofarabine in adult patients with refractory or relapsed acute myelogenous leukemia. Proc Am Soc Clin Oncol 2003; 22:587 (abstract 2360).
  • 11
    Faderl S,Gandhi V,O'Brien S, et al. Results of phase 1–2 study of clofarabine in combination with cytarabine (Ara-C) in relapsed and refractory leukemias. Blood 2005; 105: 940947.
  • 12
    Faderl S,Ferrajoli A,Wierda W, et al. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 2008; 113: 20902096.
  • 13
    Faderl S,Verstovsek S,Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006; 108: 4551.
  • 14
    Litzow MR. The therapy of relapsed acute leukemia in adults. Blood Rev 2004; 18: 3963.
  • 15
    Grimwade D,Walker H,Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 93: 23222333.
  • 16
    Slovak ML,Kopechy KJ,Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and posteremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 40754083.
  • 17
    Chevallier P,Labopin M,Turlure P, et al. A new leukemia prognostic scoring system for refractory/relapsed adult acute myelogeneous leukemia patients: A GOELAMS study. Leukemia 2011; 25; 939944.
  • 18
    Santos FP,Jones D,Qiao W, et al. Prognostic value of FLT3 mutations among different cytogenetics subgroups in acute myeloid leukemia. Cancer 2010; 117: 21452155.
  • 19
    Appelbaum FR,Gundacker H,Head DR, et al. Age and acute myeloid leukemia. Blood 2006; 107: 34813485.
  • 20
    Rowe JM,Li X,Cassileth PA, et al. Very poor survival of patients with AML who relapse after achieving a first complete remission: The Eastern Cooperative oncology Group Experience. Blood 2005; 106: 162a (abstract 546).
  • 21
    Burnett AK,Russell NH,Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive J Clin Oncol 2010; 28: 23892395.
  • 22
    Faderl S,Ravandi F,Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008; 112: 16381645.
  • 23
    Kantarjian HM,Erba HP,Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010; 26: 549555.
  • 24
    Gianfaldoni G,Mannelli F,Ponziani V, et al. Early reduction of WT1 transcripts during induction chemotherapy predicts longer disease free and overall survival in acute myeloid leukemia. Haematologica 2010; 9: 833836.
  • 25
    Karp J,Ricklis R,Balakrishnan K, et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007; 110: 17621769.